Hummingbird Diagnostics GmbH

Hummingbird Diagnostics GmbH, established in 2006 and headquartered in Germany, is a health care startup that aims to revolutionize disease diagnosis and management by harnessing the predictive power of blood-borne miRNAs. The company's slogan "Harnessing the predictive power of blood-borne miRNAs" reflects its core focus on extracting deep insights into disease through the integrated analysis of both disease and immune system derived small RNA biomarkers from whole blood. Hummingbird's dual interrogation approach, which involves the analysis of signals from both disease and the host response to disease, enables the development of a highly sensitive, robust, and AI-powered platform. This platform has the potential to revolutionize how cancer and other diseases are diagnosed, treated, and managed. The most recent investment in Hummingbird Diagnostics GmbH was a Venture Round investment that took place on 01 January 2016, with GreyBird Ventures participating as the investors. This injection of funds showcases the confidence of GreyBird Ventures in the potential of Hummingbird's innovative approach to disease diagnosis and management. With its unique focus on blood-borne miRNAs and integrated analysis, Hummingbird Diagnostics GmbH presents an intriguing opportunity for venture capitalists seeking to invest in the future of health care technology.